Revenue Performance - Revenue for the three months ended September 30, 2021, was $5,568,757, a significant increase from $350,032 for the same period in 2020, primarily due to the AHP acquisition [151]. - Revenue for the nine months ended September 30, 2021, was $12,873,607, compared to $1,194,250 for the same period in 2020, also driven by the AHP acquisition [151]. Operating Expenses - Operating expenses for the three months ended September 30, 2021, were $2,012,197, compared to $1,636,889 for the same period in 2020 [147]. - General and administrative expenses for the three months ended September 30, 2021, were $1.74 million, up from $698,598 for the same period in 2020, primarily due to the AHP and AHA acquisitions [157]. - Interest expense for the three months ended September 30, 2021, was $1.56 million, compared to $18,252 for the same period in 2020, primarily due to debt related to the acquisition of AHA [162]. - Research and Development expense for the nine months ended September 30, 2021, was $208,615, down from $502,961 for the same period in 2020, due to a reduction in personnel [156]. - The company anticipates additional increases in operating expenses and capital expenditures related to developmental and marketing expenses [173]. Cash Flow and Financing - Cash of $6,011,442 was reported for the nine months ended September 30, 2021, an increase of $5,984,511 from $26,931 as of December 31, 2020 [168]. - Cash used in operating activities for the nine months ended September 30, 2021, was $3,970,719, compared to $1,557,995 for the same period in 2020 [170]. - Cash provided by financing activities for the nine months ended September 30, 2021, was $7,161,652, compared to $472,766 for the same period in 2020 [172]. - The company has no lines of credit or bank financing arrangements, relying on private placements of equity and debt instruments for operations [173]. - Future financing may not be available on acceptable terms, potentially restricting business operations [173]. - Additional issuances of equity or convertible debt securities may result in dilution to current shareholders [173]. Going Concern and Capital Requirements - There is substantial doubt about the company's ability to continue as a going concern, dependent on raising additional capital and generating profitable operations [174]. - Working capital requirements are expected to increase in line with business growth, funded through existing funds and further issuances of securities [173]. - The financial statements have been prepared assuming the company will continue as a going concern, highlighting the need for sufficient capital [174]. - The company may not be able to find alternative sources of cash or generate positive cash flow, adversely affecting business and shareholders [174].

Revenue Growth - Revenue for the three months ended June 30, 2021, was $5,290,505, a significant increase from $378,588 for the same period in 2020, primarily due to the AHP acquisition [134]. - Revenue for the six months ended June 30, 2021, was $7,304,850, compared to $844,218 for the same period in 2020, also driven by the AHP acquisition [134]. Operating Expenses - Operating expenses for the three months ended June 30, 2021, totaled $2,039,436, up from $1,796,351 in 2020, reflecting increased costs associated with the AHP and AHA acquisitions [131]. - General and administrative expenses for the six months ended June 30, 2021, were $6,200,000, up from $2,200,000 in 2020, largely due to stock-based compensation and acquisitions [140]. - Interest expense for the three months ended June 30, 2021, was $2,000,000, compared to $249,283 for the same period in 2020, primarily due to debt accretion related to the AHA acquisition [142]. - Research and Development expense for the three months ended June 30, 2021, was $59,629, down from $314,255 in 2020, reflecting a reduction in personnel [137]. - Management anticipates additional increases in operating expenses and capital expenditures related to developmental and marketing expenses [155]. Financial Position - Cash as of June 30, 2021, was $4,795,175, an increase of $4,768,244 or 177% compared to $26,931 as of December 31, 2020 [149]. - Cash used in operating activities for the six months ended June 30, 2021, was $2,392,675, compared to $1,368,229 for the same period in 2020, indicating increased operational cash outflow [151]. - Cash provided by financing activities for the six months ending June 30, 2021, was $3,272,652, a significant increase from $369,073 for the same period in 2020 [153]. - Proceeds from the sale of common stock amounted to $3,195,000, contributing to the overall financing activities [153]. Capital Raising and Concerns - The company anticipates raising capital in private markets to support business expansion, although there is no guarantee of favorable terms [150]. - The company expects working capital requirements to increase in line with business growth, funded through existing funds and further securities issuances [155]. - There is substantial doubt about the company's ability to continue as a going concern, dependent on raising additional capital and generating profitable operations [156]. - The company has no lines of credit or bank financing arrangements, relying on private placements of equity and debt instruments for funding [155]. - Additional issuances of equity or convertible debt securities may dilute current shareholders and could have senior rights that impact common stock [155]. - The company may face challenges in raising adequate funds on acceptable terms, which could restrict business operations [156]. - Future financing may not be available, impacting the company's ability to pursue new business opportunities [156]. - The financial statements have been prepared assuming the company will continue as a going concern, highlighting the need for positive cash flow [156].

Part I — Financial Information [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) Q1 2021 acquisitions of AHP and AHA dramatically transformed the company's financial position, boosting assets and revenue while widening net loss due to increased operating costs and stock-based compensation [Condensed Consolidated Balance Sheets](index=3&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2021, the company's total assets dramatically increased to $75.9 million from $169.9 thousand at year-end 2020, primarily driven by goodwill and intangible assets from recent acquisitions, while total liabilities rose to $49.7 million, shifting stockholders' equity from a deficiency to a positive $66.3 million Condensed Consolidated Balance Sheet Highlights (Unaudited) | Balance Sheet Item | March 31, 2021 | December 31, 2020 | | :--- | :--- | :--- | | **Total Assets** | **$75,935,655** | **$169,857** | | Goodwill | $54,978,298 | $— | | Intangible assets, net | $9,653,956 | $— | | Cash | $3,741,458 | $26,931 | | **Total Liabilities** | **$49,671,614** | **$1,303,652** | | Accounts payable and accrued expenses | $4,336,217 | $695,424 | | **Total Stockholders' Equity (Deficiency)** | **$66,264,041** | **($1,133,795)** | [Condensed Consolidated Statements of Operations](index=4&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) For the three months ended March 31, 2021, sales surged to $2.01 million, a 333% increase from $465,630 in the same period of 2020, primarily due to acquisitions, yet the net loss widened significantly to $4.44 million from $1.12 million year-over-year, driven by a sharp rise in operating expenses including substantial stock-based compensation Condensed Consolidated Statements of Operations (Unaudited) | Metric | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | | :--- | :--- | :--- | | Sales | $2,014,345 | $465,630 | | Gross Profit | $426,872 | $266,502 | | Total Operating Expenses | $4,576,795 | $1,206,417 | | Loss from Operations | ($4,149,923) | ($939,915) | | Net Loss Attributable to Clinigence | ($4,444,559) | ($1,122,730) | | Net Loss per Share | ($0.24) | ($0.24) | [Condensed Consolidated Statements of Changes in Stockholders' Equity](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders'%20Equity) During the first quarter of 2021, stockholders' equity increased from a deficit of $1.1 million to a positive $66.3 million, primarily driven by the issuance of common stock valued at $68.0 million for business acquisitions and $3.9 million in stock-based compensation, partially offset by a net loss of $4.5 million - The company issued **33,009,382** shares of common stock valued at **$67,999,339** for business acquisitions in Q1 2021[13](index=13&type=chunk) - Stock-based compensation added **$3,882,637** to stockholders' equity during the quarter[13](index=13&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the three months ended March 31, 2021, the company's cash position increased by $3.7 million, ending the period at $3.74 million, with net cash used in operating activities of $567,063, significant cash inflow from investing activities of $3.89 million, and $393,323 provided by financing activities Cash Flow Summary (Unaudited) | Cash Flow Activity | Three Months Ended March 31, 2021 | | :--- | :--- | | Net Cash Used in Operating Activities | ($567,063) | | Net Cash Provided by Investing Activities | $3,888,267 | | Net Cash Provided by Financing Activities | $393,323 | | **Net Increase in Cash** | **$3,714,527** | | **Cash - End of Period** | **$3,741,458** | - Non-cash investing and financing activities included the issuance of **$67,999,339** in common stock for the acquisition of subsidiaries[16](index=16&type=chunk) [Notes to Consolidated Financial Statements](index=7&type=section&id=Unaudited%20Condensed%20Notes%20to%20Consolidated%20Financial%20Statements) The notes detail significant corporate events and accounting policies, including the February 2021 mergers with AHP Management Inc. and Accountable Healthcare America, Inc. (AHA), which led to substantial goodwill and intangible assets, the company's Variable Interest Entity (VIE) structure with AHPIPA, a 'Going Concern' warning due to historical losses and a working capital deficit, and subsequent events like additional stock sales and a letter of intent to acquire Procare Health Inc - On February 26, 2021, the company consummated mergers with AHP Management Inc. and Accountable Healthcare America, Inc. (AHA)[21](index=21&type=chunk)[28](index=28&type=chunk) - The company's financial statements include a 'Going Concern' warning due to an accumulated deficit of **$22.7 million** and a working capital deficit, raising substantial doubt about its ability to continue operations for the next twelve months without additional funding[70](index=70&type=chunk) - The company consolidates AHPIPA as a Variable Interest Entity (VIE), as it is the primary beneficiary with the power to direct its significant non-clinical economic activities[25](index=25&type=chunk)[112](index=112&type=chunk) - Subsequent to the quarter end, the company sold **814,286** shares of common stock for proceeds of **$1.22 million** and entered into a binding Letter of Intent to acquire Procare Health Inc[117](index=117&type=chunk)[118](index=118&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=26&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's post-acquisition transformation, highlighting significant revenue growth and increased net loss, while addressing liquidity and the 'going concern' note Q1 2021 vs Q1 2020 Results of Operations | Metric | Q1 2021 | Q1 2020 | % Change | | :--- | :--- | :--- | :--- | | Total Revenue | $2,014,345 | $465,630 | 332.61% | | Gross Profit | $426,872 | $266,502 | 60.18% | | Loss from Operations | ($4,149,923) | ($939,915) | 341.52% | | Net Loss | ($4,484,140) | ($1,122,730) | 299.40% | - The increase in revenue was primarily attributable to the AHP acquisition, which added **$1.59 million** in capitation revenue[135](index=135&type=chunk)[136](index=136&type=chunk) - General and administrative expenses increased significantly, primarily due to stock-based compensation expense of **$3.9 million** and costs from the AHP and AHA acquisitions[140](index=140&type=chunk) - The company had cash of **$3.7 million** as of March 31, 2021, and believes it has sufficient liquidity for the next 12 months, but notes that its financial statements contain a 'going concern' explanatory paragraph[147](index=147&type=chunk)[153](index=153&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=31&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company states that this item is not required for a smaller reporting company - As a smaller reporting company, quantitative and qualitative disclosures about market risk are not required[154](index=154&type=chunk) [Controls and Procedures](index=31&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, evaluated the company's disclosure controls and procedures as of March 31, 2021, concluding they were effective, with no material changes to internal control over financial reporting identified during the first fiscal quarter of 2021 - Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2021[155](index=155&type=chunk) - There were no changes in internal control over financial reporting during the quarter that materially affected, or are reasonably likely to materially affect, internal controls[156](index=156&type=chunk) Part II — Other Information [Legal Proceedings](index=31&type=section&id=Item%201.%20Legal%20Proceedings) The company reports that it is not a party to any material litigation as of March 31, 2021 - The Company is not a party to any litigation that is material to ongoing operations as of the period ended March 31, 2021[159](index=159&type=chunk) [Risk Factors](index=32&type=page&id=Item%201A.%20Risk%20Factors) The company states there have been no material changes in its risk factors from those disclosed in its Annual Report on Form 10-K for the year ended December 31, 2020, directing investors to that report for a full discussion of risks - There have been no material changes in the company's risk factors from those disclosed in the Annual Report on Form 10-K for the year ended December 31, 2020[161](index=161&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=32&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities for the period - None reported[164](index=164&type=chunk) [Defaults upon Senior Securities](index=32&type=section&id=Item%203.%20Defaults%20upon%20Senior%20Securities) The company reported no defaults upon senior securities - None reported[164](index=164&type=chunk) [Other Information](index=32&type=section&id=Item%205.%20Other%20Information) The company reported no other information - None reported[164](index=164&type=chunk) [Exhibits](index=32&type=section&id=Item%206.%20Exhibits) The report lists the exhibits filed, which include certifications by the Chief Executive Officer and Chief Financial Officer pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 - Exhibits filed include CEO and CFO certifications under Sarbanes-Oxley Sections **302** and **906**[164](index=164&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-53862 CLINIGENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 11-3363609 (I.R.S. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended September 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 000-53862 Clinigence Holdings, Inc. (Exact name of small business issuer as specified in its charter) (State or other jurisdiction of incorporation or organizatio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended June 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 000-53862 Clinigence Holdings, Inc. (Exact name of small business issuer as specified in its charter) Delaware 11-3363609 (State or other jurisdiction of incorporation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended March 31, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 000-53862 Clinigence Holdings, Inc. (Exact name of small business issuer as specified in its charter) (State or other jurisdiction of incorporation or organization) 5 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-53862 CLINIGENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 11-3363609 (I.R.S. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended September 30, 2019 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 000-53862 Clinigence Holdings, Inc. (Formerly known as iGambit Inc.) (Exact name of small business issuer as specified in its charter) (State or other jurisdictio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended June 30, 2019 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 000-53862 iGambit Inc. (Exact name of small business issuer as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 11-336 ...